Autologous Muscle-Derived Cell Therapy for Female Stress Urinary Incontinence: A Systematic Review and Meta-analysis of Efficacy, Safety, and Patient-Reported Outcomes
Medical Principles and Practice · 2026-11-06
DOI: 10.1159/mpp/adpag040 ↗Abstract
Abstract Background: Autologous muscle-derived cell (MDC) therapy is a regenerative option for stress urinary incontinence (SUI), but its overall efficacy and safety remain uncertain. Methods: We conducted a PRISMA-compliant systematic review and meta-analysis of clinical studies from 2000 onwards evaluating autologous MDC injections for SUI. PubMed, Scopus, Web of Science, and Cochrane CENTRAL were searched until November 2025, and citation tracking was performed. We included randomized and non-randomized studies in adults or children with SUI treated by periurethral, transurethral, or intrasphincteric MDC injections, reporting continence or safety outcomes. Results: Of 885 records, 15 studies (5 RCTs and 10 non-RCTs; 1,140 participants) met the inclusion criteria. Across three RCTs, MDCs did not significantly improve mean incontinence episode frequency (IEF) reduction versus placebo and did not significantly increase the proportion achieving ≥50% IEF reduction, but significantly increased the likelihood of ≥75% IEF reduction. A trend toward more patients achieving ≤1 stress incontinence episode favoured MDCs but was not statistically significant. Treatment-related adverse events (TRAEs) were similar between MDCs and placebo, and pooled single-arm data showed low overall TRAE rates (∼5–11%), without clear differences by follow-up duration, injection route, imaging guidance, or use of electrical stimulation. Single-arm meta-analyses demonstrated significant improvements in IIQ-7, IQOL, UDI-6, and pad test leakage, despite substantial heterogeneity. Conclusions: MDC therapy for SUI appears safe and may increase the probability of high-level symptom improvement and quality-of-life gains, although average benefits over placebo are modest. Larger, standardized trials are needed to refine patient selection and clarify long-term outcomes.
EUVIMED